Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation show a high response to EGFRtyrosine kinase inhibitor (EGFR-TKI). Clinically, EGFR-positive NSCLC acquires several resistance mechanisms during EGFR-TKI treatment, such as the emergence of a secondary mutation (T790M), MET gene amplification, and transformation to small cell lung cancer. However, the mechanism of resistance to afatinib, a second-generation EGFR-TKI, remains unclear. In this study, we prospectively investigate the mechanism of resistance to afatinib using proteomic analyses.
Introduction
In recent years, treatment advances against non-small cell lung cancer (NSCLC) with driver mutations in genes, such as epidermal growth factor receptor (EGFR), have revealed that patients with driver mutations show greater responses to tyrosine kinase inhibitors (TKIs) compared to chemotherapy. [1] Among EGFR-positive NSCLC patients, treatment with EGFR-TKIs showed significantly longer progression-free survival (PFS) compared to platinum doublet therapy. [2] [3] [4] [5] Afatinib, a second-generation EGFR-TKI, is an irreversible ErbB family binder and blocker that inhibits EGFR, HER2, and HER4. [6] [7] [8] At present, gefitinib, erlotinib, and afatinib have been approved for EGFR-positive NSCLC patients as a first-line treatment. For the first time, afatinib among EGFR-TKIs showed significantly longer PFS and overall survival compared to platinum doublet therapy in patients with deletion of exon 19 in EGFR. [9] Moreover, afatinib significantly prolonged the PFS compared to gefitinib. [10] On the other hand, strong digestive organ toxicity and dermal toxicity were observed; therefore, afatinib was not recommended in poor performance status and the elderly. However, by adjusting the amount of medicine to reduce these side effects, patients were reported to be able to continue afatinib therapy with a therapeutic effect equivalent to that reported previously in a study including the elderly.
Almost all EGFR-positive NSCLC patients acquire several resistance mechanisms during EGFR-TKIs treatment, such as the emergence of a secondary mutation (T790M), MET gene amplification, and transformation to small cell lung cancer. [12, 13] Of these, EGFR-T790M is the most common resistance mechanism and found in approximately 50% of cases of resistance during the administration of first-generation EGFRTKIs. [12, 14] Osimertinib, a third-generation EGFR-TKI, is approved for EGFR-T790M-positive NSCLC patients who experienced disease progression during the first and/or second EGFR-TKI treatment because the AURA-3 study reported that osimertinib significantly prolonged PFS compared to platinumpemetrexed therapy in EGFR-T790M-positive NSCLC patients after resistance. [15] Little is known regarding the presence of associations between the different responses to EGFR-TKIs and the emergence of T790M. As EGFR-T790M detection was reported to be associated with the initial EGFR-TKI duration and response rate, [16] afatinib treatment is expected to be associated with the greater emergence of EGFR-T790M in basic and clinical research.
Recently, advances in the proteomic analysis have revealed the anomalies in genes and proteins in increased detail. At this time, we are prospectively investigating the tumor proteome before afatinib therapy and after disease progression using proteomic analysis. The primary endpoint is to explore anomalies in proteins that can be candidates for the resistance factor of afatinib. The secondary endpoint is to explore the protein abnormalities affecting the PFS, objective response rate (ORR), and disease control rate (DCR) in afatinib therapy.
Methods and analysis

Study design
The study is a prospective observational study. Figure 1 depicts a flowchart of the study.
Study setting
Four hospitals agreed to participate in this study. The study protocol was approved by the institutional review board of each hospital. Written informed consent was obtained from all the patients before registration in accordance with the Declaration of Helsinki. The samples are being analyzed by the National Cancer Center Hospital. At least annual independent monitoring is planned in accordance with the Japanese clinical trial guidelines.
Participants
The inclusion criteria are as follows: 
Dose and treatment regimens
Afatinib (40 mg) or gefitinib (250 mg) OD tablet is administered orally. Oral administration of these drugs is continued until disease progression or the criteria for discontinuation.
Rationale for the setting of the number of enrolled subjects
As this study is a prospective observational study for biomarker detection, the number of enrolled subjects is not set. Enrollment of 35 subjects who met the eligibility criteria until March 2020 was planned.
Proteomic analysis
Samples at diagnosis and upon rebiopsy after resistance are cryopreserved at À80°C after washing with physiological saline. If rebiopsy samples are diagnosed with NSCLC, proteomic analysis will be performed at National Cancer Center Hospital as follows: comprehensive protein expression analysis using mass spectrometry and exhaustive phosphoenzyme activity analysis using PamStation.
Statistical methods
PFS: survival curve, median (Kaplan-Meier method), confidence interval of the median (Brookmeyer and Crowley method), and standard error of the annual rate (Greenwood method).
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ORR: response rate and its two-sided 95% confidence interval (Wilson method). Statistical significance is considered when the lower limit of the estimated confidence interval exceeds a threshold of 35%.
DCR: disease control rate and its two-sided 95% confidence interval (Wilson method).
Ethics
The trial received ethical approval from the Ethics Committee of Kyoto Prefectural University of Medicine, Kyoto, Japan (number: ERB-C-1106). The trial is subject to the supervision and management of the Ethics Committee.
Trial status
This study opened to recruitment in May 2018, with a planned last follow-up in March 2020. As of August 2018, 4 subjects have been enrolled.
Discussion
Ultimately, EGFR-positive NSCLC patients acquire resistance to EGFR-TKI during therapy. EGFR-T790M, which is found in approximately 50% of patients after resistance, is one of the several resistance mechanisms involved. [12, 14] If we detect T790M in rebiopsy samples, EGFR-T790M-positive patients could be administrated osimertinib. Several investigations have shown T790M was significantly detected in EGFR-positive NSCLC patients with a longer duration of initial EGFR-TKI and a higher response rate to initial EGFR-TKI. Afatinib differs from firstgeneration EGFR-TKIs in binding and blocking the ErbB family that inhibits EGFR, HER2, and HER4 irreversibly as shown in basic studies. [6] [7] [8] Moreover, afatinib therapy was superior to gefitinib in clinical research with respect to PFS and ORR. [10] The emergence of T790M might show a greater increase during afatinib therapy than during gefitinib therapy, while resistance mechanisms differing from T790M, MET amplification, and transformation to small cell lung cancer might emerge. Therefore, evaluation of the tumor proteome before treatment and after the acquisition of resistance using proteomic analysis is needed.
